<DOC>
	<DOC>NCT01611428</DOC>
	<brief_summary>A study to assess the absolute bioavailability of ipragliflozin in healthy subjects.</brief_summary>
	<brief_title>Absolute Bioavailability Study With Ipragliflozin</brief_title>
	<detailed_description />
	<criteria>Body Mass Index (BMI) more than or equal to 18.5 and less than 30.0 kg/m2 Any of the liver function tests above the upper limit of normal. Abnormal pulse and/or blood pressure measurements at the prestudy visit as follows: Pulse &lt;40 or &gt;90 bpm; mean systolic blood pressure &gt;140 mmHg; mean diastolic blood pressure &gt;90 mmHg (blood pressure measurements taken in triplicate after subject has been resting in supine position for 5 min; pulse will be measured automatically) A QTc interval of &gt;430 ms (males) or &gt; 450 ms (females) consistently after duplicate measurements, a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Ipragliflozin</keyword>
	<keyword>Healthy</keyword>
	<keyword>Absolute Bioavailability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>